Rupert Wolfgang Strauss

Dr. Rupert Wolfgang Strauss


Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 January 2022 in PLOS ONE
Verified
Journal Article
Open access
PDF file
MGMarlene Glatz
Marlene Glatz
RRRegina Riedl
Regina Riedl
WGWilfried Glatz
Wilfried Glatz
MSMona Schneider
Mona Schneider
AWAndreas Wedrich
Andreas Wedrich
RSRupert Wolfgang Strauss
Rupert Wolfgang Strauss
Purpose: To assess the prevalence and causes of visual impairment and blindness in a Central European country. The findings may have implications for the planning of further research and development of therapies in order to prevent blindness. Setting: Department of Ophthalmology, Medical University of Graz, Austria. Design: Retrospective, epidemiological study. Methods: The database of the Main Confederation of Austrian Social Insurances was searched for patients with visual impairment, legal blindness or deaf-blindness. This database gathers data from patients of all insurance providers in the country who receive care due to visual impairment and blindness. To determine the prevalence of these conditions, the number of all entries recorded in February 2019 was evaluated. Additionally, all new entries between (January 1st,) 2017, and (December 31st,) 2018, were analysed for distinct characteristics, such as sex, the cause of blindness/visual impairment, and age. Since health care allowances can provide a considerable source of income (459.90€-936.90€ per month), good coverage of practically all patients who are blind and visually impaired in the country can be assumed. Results: On February 2nd, 2019, 17,730 patients with visual impairments, blindness or deaf-blindness were registered in Austria, resulting in a prevalence of these diagnoses of 0.2% in the country. During the observational period from 2017 to 2018, 4040 persons met the inclusion criteria. Of these, 2877 were female (65.3%), and 1527 were male (34.7%). The mean age was 75.7 ± 18.0 years (median 82). Most patients (n = 3675, 83.4%) were of retirement age, while 729 (16.6%) were working-age adults or minors. In total, an incidence of 25.0 (95% confidence limit (CL) 24.3–25.8) per 100,000 person-years was observed from 2017 to 2018. A higher incidence was observed for females (32.2, 95% CL 31.0–33.3) than for males (17.7, 95% CL 16.8–18.5). Incidences where higher for males in lower age groups (e.g. 10–14 years: rate ratio RR = 2.7, 95% CL 1.1–6.8), and higher for females in higher age groups (e.g. 70–74 years: RR = 0.6, 95% CL 0.5–0.8). In total, the most frequent diagnoses were macular degeneration (1075 persons, 24.4%), other retinal disorders (493 persons, 11.2%) and inherited retinal and choroidal diseases (IRDs) (186 persons, 4.2%). Persons with IRDs were significantly younger compared to persons with macular degeneration or retinal disorders (IRDs: median 57, range 2–96 vs 83, 5–98 and 82, 1–98 years, p<0.001). For persons of retirement age, macular degeneration, other retinal disorders and glaucoma were the three most frequent diagnoses. In contrast, among working-aged adults and children, IRDs were the leading cause of visual impairment and blindness (103 persons, 14.1%). Conclusion: These data show that IRDs are the leading cause of blindness and visual impairment in working-aged persons and children in Austria. Thus, these findings suggest to draw attention to enhance further research in the fields of emerging therapies for IRDs.

20 April 2023 in British Journal of Ophthalmology
Verified
Journal Article
Closed access
PDF file
GSGernot Schließleder
Gernot Schließleder
Angelos KalitzeosAngelos Kalitzeos
Angelos Kalitzeos
MKMelissa Kasilian
Melissa Kasilian
NSNavjit Singh
Navjit Singh
ZWZiyuan Wang
Ziyuan Wang
RSRupert Wolfgang Strauss
Rupert Wolfgang Strauss
Background/aims: The purpose of this study was to investigate retinal structure in detail of subjects with autosomal-dominant (AD) and autosomal-recessive (AR)PROM1-associated retinal degeneration (PROM1-RD), study design: institutional, cross-sectional study.Methods: Four eyes from four subjects (three with AD and one with AR)PROM1-RD were investigated by ophthalmic examination including best-corrected visual acuity (BCVA) and multimodal retinal imaging: fundus autofluorescence (FAF), spectral-domain optical coherence tomography (SD-OCT) and adaptive optics scanning light ophthalmoscopy. Quantitative assessment of atrophic lesions determined by FAF, thickness of individual retinal layers and cone photoreceptor quantification was performed.Results: BCVA ranged from 20/16 to 20/200. Initial pathological changes included the presence of hyperautofluorescent spots on FAF imaging, while later stages demonstrated discrete areas of atrophy. In all patients, thinning of the outer retinal layers on SD-OCT with varying degrees of atrophy could be detected depending on disease-causing variants and age. Cone density was quantified both in central and/or at different eccentricities from the fovea. Longitudinal assessments were possible in two patients.Conclusions: PROM1-RD comprises a wide range of clinical phenotypes. Depending on the stage of disease, the cone mosaic inPROM1-RD is relatively preserved and can potentially be targeted by cone-directed interventions.

18 July 2024 in Ophthalmic Research
Verified
Journal Article
Open access
PDF file
RSRupert Wolfgang Strauss
Rupert Wolfgang Strauss
LLLang Lang
Lang Lang
AHAlexander Ho
Alexander Ho
AJAnamika Jha
Anamika Jha
MIMichael Ip
Michael Ip
FGfor the ProgStar Study Group
for the ProgStar Study Group
Introduction: To evaluate the progression of atrophy as determined by spectral-domain optical coherence tomography (SD-OCT) in patients with molecularly confirmed ABCA4-associated Stargardt disease type 1 (STGD1) over a 24-month period in a multicenter prospective cohort study. Methods: SD-OCT images from 428 eyes of 236 patients were analyzed. Change of mean thickness (MT) and intact area were estimated after semi-automated segmentation for the following individual layers in the central subfield (CS), inner ring (IR) and outer ring (OR) of the ETDRS grid: retinal pigment epithelium (RPE), outer segments (OS), inner segments (IS), outer nuclear layer (ONL) inner retina (IR) and total retina (TR). Results: Statistically significant decreases of all outer retinal layers (RPE, OS, IS, and ONL) could be observed over a 24-month period both in decline of mean retinal thickness and intact area (p<.0001, respectively); whereas the inner retina showed an increase of retinal thickness in the central subfield and inner ring and remained unchanged in the outer ring. Conclusions: Significant loss could be detected in outer retinal layers by SD-OCT over a 24-month period in patients with STGD1. Loss of thickness and/or intact area of such layers may serve as potential endpoints for clinical trials that aim to slow down the disease progression of STGD1.

17 November 2023 in American Journal of Ophthalmology
Verified
Journal Article
Open access
MGManuel Großpötzl
Manuel Großpötzl
RRRegina Riedl
Regina Riedl
GSGernot Schließleder
Gernot Schließleder
ZHZhihong Hu
Zhihong Hu
MMMichel Michaelides
Michel Michaelides
RSRupert Wolfgang Strauss
Rupert Wolfgang Strauss
PURPOSE: To evaluate the progression of atrophy as determined by spectral -domain optical coherence tomography (SD-OCT) in patients with molecularly confirmed PROM1-associated retinal degeneration (RD) over a 24month period. DESIGN: International, multicenter, prospective case series. METHODS: A total of 13 eyes (13 patients) affected with PROM1-associated RD were enrolled at 5 sites and SD-OCT images were obtained at baseline and after 24 months. Loss of mean thickness (MT) and intact area were estimated after semi -automated segmentation for the following individual retinal layers in the central subfield (CS), inner ring, and outer ring of the ETDRS grid: retinal pigment epithelium (RPE), outer segments (OS), inner segments (IS), outer nuclear layer (ONL), inner retina (IR), and total retina (TR). RESULTS: Statistically significant losses of thickness of RPE and TR were detected in the CS and inner ring and of ONL and IS in the outer ring (all P < .05); a statistically significant decrease in the intact area of RPE and IS was observed in the inner ring, and of ONL in the outer ring (all P < .05); the change in MT and the intact area of the other layers showed a trend of decline over an observational period of 24 months. CONCLUSIONS: Significant thickness losses could be detected in outer retinal layers by SD-OCT over a 24 -month period in patients with PROM1-associated retinal degeneration. Loss of thickness and/or intact area of such layers may serve as potential endpoints for clinical trials that aim to slow down the disease progression of PROM1-associated retinal degeneration. (Am J Ophthalmol 2024;259: 109-116. (c) 2023 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY license ( http://creativecommons.org/licenses/by/4.0/ ))

10 January 2023 in Journal of Ophthalmology
Verified
Journal Article
Open access
PDF file
HKHaidar Khalil
Haidar Khalil
SMSiegfried Mariacher
Siegfried Mariacher
RSRupert Wolfgang Strauss
Rupert Wolfgang Strauss
DPDominika Podkowinski
Dominika Podkowinski
KWKlemens Waser
Klemens Waser
MBMatthias Bolz
Matthias Bolz
Purpose. In Austria, anti‐VEGF therapies are reimbursed only in clinical settings. This study aimed to describe the outcome of a treat and extend regimen (TER) with aflibercept for diabetic macular edema (DME) in a network of practitioners. Methods. In a prospective study over 36 months, patients with DME were treated with a loading dose of aflibercept and further on with adjusted treatment intervals based on optical coherence tomography (OCT) findings. All patients were monitored in an outpatient setting by regional ophthalmologists, and the treatment was administered in the clinic. Main outcome parameters were best‐corrected visual acuity (BCVA) from baseline to the last regular visit. Number of visits at the practitioner’s office as well as the number of injections were secondary outcome parameters. Results. Thirty‐three patients completed the study at their final visit. BCVA improved significantly by 5.8 letters between baseline and the final visit from 70.4 letters at baseline (p = 0.004). Patients visited the practitioner’s office 12.8 times in the observation period of 36 months. 3.7, 5.1, and 3.9 visits were performed, respectively, in the first, second, and third years, and 25.5 ± 7.9 injections were performed. The mean interval of injections over the observation period was 6.2 ± 2.2 in weeks. Conclusion. The treat and extend regimen was valuable for treating patients with DME in this specific setting. The functional results of this study were comparable to those of other real‐world evaluations. Adherence to the same treating institution seems to be important to avoid differences in therapeutic decision making and may also increase patient’s compliance.

27 February 2024 in Spektrum der Augenheilkunde
Verified
Journal Article
Open access
PDF file
MEMarkus Eidherr
Markus Eidherr
HJHildrun Jarz-Lackner
Hildrun Jarz-Lackner
MBMatthias Bolz
Matthias Bolz
TBTalin Barisani
Talin Barisani
RSRupert Wolfgang Strauss
Rupert Wolfgang Strauss
Zusammenfassung: Etwa 5–10 % aller Uveitisfälle treten bei Kindern auf. Die Erkrankung verläuft oft ohne Symptome, was zu einer verzögerten Diagnose und möglichen Schäden an den Augen führen kann. Infektiöse und nichtinfektiöse Ursachen können zur Uveitis führen, wobei die juvenile idiopathische Arthritis die häufigste Ursache bei Kindern und Jugendlichen ist. Die Behandlung hängt von der Ursache ab und kann eine Immunsuppression beinhalten. Katarakt, Glaukom und Amblyopie sind die häufigsten Komplikationen, die das Sehvermögen beeinträchtigen können. Regelmäßige Kontrollen sind auch nach Inaktivität der Uveitis wichtig, um erneute Entzündungsschübe frühzeitig zu erkennen und die Therapie anzupassen. Das Ziel dieser Arbeit ist es, einen Überblick über das klinische Erscheinungsbild, potenzielle Ursachen, Therapiemöglichkeiten und Komplikationen der Uveitis bei Kindern zu geben.